Home Cart Sign in  
Chemical Structure| 70831-56-0 Chemical Structure| 70831-56-0

Structure of L-Chicoric Acid
CAS No.: 70831-56-0

Chemical Structure| 70831-56-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

L-Chicoric acid, a natural product isolated and purified from the herbs of Echinacea purpurea, is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase in vitro and of HIV-1 replication in tissue culture.

Synonyms: (-)-Chicoric acid; trans-Caffeoyltartaric acid; NSC 99173

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of L-Chicoric Acid

CAS No. :70831-56-0
Formula : C22H18O12
M.W : 474.37
SMILES Code : O=C(O)[C@H](OC(/C=C/C1=CC=C(O)C(O)=C1)=O)[C@@H](OC(/C=C/C2=CC=C(O)C(O)=C2)=O)C(O)=O
Synonyms :
(-)-Chicoric acid; trans-Caffeoyltartaric acid; NSC 99173
MDL No. :MFCD22683653
InChI Key :YDDGKXBLOXEEMN-IABMMNSOSA-N
Pubchem ID :5281764

Safety of L-Chicoric Acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
PBMCs 0, 10, 50, 100 µM To evaluate the effect of CA on PBMC proliferation, it was found that CA could stimulate PBMC proliferation and enhance the cytotoxic effect of immune cells on tumor cells. Cell Commun Signal. 2025 Mar 14;23(1):137
SKOV3 cells 0, 10, 50, 100 µM To evaluate the effect of CA on ovarian cancer cell proliferation, it was found that CA could not directly inhibit OC cell proliferation. Cell Commun Signal. 2025 Mar 14;23(1):137
Vascular Smooth Muscle Cells (VSMCs) 10, 50, 100 μM 24 hours CA pretreatment dose-dependently suppressed PDGF-BB-induced VSMC phenotypic alteration, proliferation and migration. Redox Biol. 2018 Apr;14:656-668

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice PBMC-PDX model Intraperitoneal injection 50 mg/kg To evaluate the combined effect of CA with aPD-1/aPD-L1 antibodies, it was found that CA enhanced the therapeutic efficacy of aPD-L1 and aPD-1, significantly reducing tumor volume. Cell Commun Signal. 2025 Mar 14;23(1):137
Sprague-Dawley rats Carotid artery ligation model Gastric gavage 50 mg/kg/day Once daily for 8 weeks CA treatment prevented intimal hyperplasia and vascular remodeling in rat models of carotid artery ligation in vivo. Redox Biol. 2018 Apr;14:656-668

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.54mL

2.11mL

1.05mL

21.08mL

4.22mL

2.11mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories